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Abstract.  Cystic fibrosis (CF) is caused by mutations 
in the cystic fibrosis transmembrane  conductance regu- 
lator (CFTR), a membrane glycoprotein that forms 
C1- channels.  Previous work has shown that when 
some CF-associated mutants of CFTR are expressed in 
heterologous cells, their glycosylation is incomplete. 
That observation led to the hypothesis that such mu- 
tants are not delivered to the plasma membrane where 
they can mediate CI- transport.  Testing this hypothesis 
requires localization of CFTR in nonrecombinant cells 
and a  specific determination of whether CFTR is in 
the apical membrane of normal and CF epithelia.  To 
test the hypothesis, we used primary cultures of air- 
way epithelia grown on permeable supports because 
they polarize and express the CF defect in apical C1- 
permeability.  Moreover, their dysfunction contributes 
to disease.  We developed a  semiquantitative assay, 
using nonpermeabilized epithelia,  an antibody directed 
against an extracellular epitope of CFTR, and large 
(1/zm) fluorescent beads which bound to secondary 
antibodies. We observed specific binding to airway epi- 
thelia from non-CF subjects, indicating that CFTR is 
located in the apical membrane.  In contrast, there was 
no specific binding to the apical membrane of CF air- 
way epithelia.  These data were supported by qualita- 
tive studies using confocal microscopy: the most 
prominent immunostaining  was in the apical region of 
non-CF cells and in cytoplasmic regions of CF cells. 
The results indicate that CFTR is either missing from 
the apical membrane of these CF cells or it is present 
at a much reduced level. The data support the pro- 
posed defective delivery of some CF-associated mu- 
tants to the plasma membrane and explain the lack of 
apical C1- permeability in most CF airway epithelia. 
C 
YSTIC fibrosis (CF) ~ is an autosomal recessive dis- 
ease caused by mutations in the gene encoding the 
cystic fibrosis transmembrane conductance regulator 
(CFTR) (8, 15, 22, 28, 30). Recent studies have shown that 
CFTR is a CI- channel  (2,  3, 6, 21) which is regulated  by 
phosphorylation  with  cAMP-dependent protein kinase  (7, 
10, 29, 32) and by nucleoside Wiphosphates (1). The proper- 
ties  of recombinant CFTR CI- channels  and those of the 
cAMP-regulated  apical  membrane  C1-  permeability  are 
similar  (5)  and  CFTR  has  been  immunocytochemically 
localized  in the apical region of several epithelia  and in the 
apical membrane of C1- secreting,  intestinal  epithelial  cell 
lines  (12, 14, 26). These observations indicate  that CFTR 
generates the cAMP-regulated  apical membrane C1- perme- 
ability of normal epithelia.  They are also consistent with the 
observation that CF epithelia  lack such a CI- permeability 
(27). 
There is, however, considerable uncertainty about how CF- 
associated mutations lead to C1- impermeability.  Mutations 
1. Abbreviations  used in this paper: CF, cystic fibrosis; CFTR, cystic fibro- 
sis transmembrane conductance regulator. 
in CFTR could result in a loss of C1- permeability in one of 
two general ways: the mutated CFTR channel might not be 
delivered to the apical membrane where it normally medi- 
ates C1- permeability,  or the mutated channel  might reach 
the plasma membrane, but have little or no function. It is also 
possible that some mutations could lead to a defect in both 
delivery and function. 
Recent studies (9, 19) indicate that several CF-associated 
mutations,  including the most common (deletion of phenyl- 
alanine at position 508, CFTRAF508) (22, 24), lead to in- 
complete protein  processing.  These  observations  suggest 
that the mutant proteins are retained in the ER rather than 
being transported to the plasma membrane. This inference 
was based on the finding that wild-type CFTR expressed in 
heterologous cells underwent two stages of glycosylation,  a 
core glycosylation  (endoglycosidase  H sensitive) character- 
istic of processing in the ER, and more extensive glycosyla- 
tion characteristic  of processing in the Golgi complex. In 
contrast,  CFTRAF508 only underwent core glycosylation. 
This result  suggested that the mutant protein did not reach 
the Golgi complex and was not delivered to the plasma mem- 
brane.  Of nine CF-associated mutants that were studied,  six 
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cAMP-stimulated halide effiux  as assessed using the SPQ as- 
say (19).  Incomplete glycosylation does not in itself cause 
C1- impermeability, because a protein that lacked glycosy- 
lation sites (constructed by site-directed mutagenesis) was 
present in the plasma membrane and had normal C1- chan- 
nel activity (9).  Three of the nine CF-associated mutants 
were processed appropriately, but still failed to generate 
cAMP-regulated halide ettlux, suggesting that in those cases 
the protein was transported normally but had little or no 
channel  function.  Because the  incompletely glycosylated 
mutants represent well over 70% of all CF chromosomes, it 
was proposed that defective trafficking of CFTR is the mo- 
lecular basis for most of CE 
Several other studies have suggested the alternative: that 
mutant CFTR is processed appropriately and delivered to 
the plasma membrane.  But none of these studies directly 
tested the hypothesis. In one study (16), CFTRAF508 was 
expressed in Xenopus oocytes. A  cAMP-regulated current 
was generated that was 62% of that observed with wild-type 
CFTR. It was suggested that CFTRAF508 may be appropri- 
ately located in CF epithelia, but that cAMP levels may not 
have been elevated sufficiently in previous studies to detect 
the current. Another study of CFTR overexpressed in heter- 
ologous cells (13) indicated that CFTRAF508 retained some 
CI-  channel  activity,  although the  number  of functional 
channels in the plasma membrane appeared to be decreased. 
Neither of these studies could directly test the hypothesis, 
because they used heterologous overexpression systems and 
the cAMP-regulated current in Xenopus oocytes may reflect 
differences in protein processing in amphibian oocytes as 
compared to mammalian cells.  A  study using membrane 
fractionation of cultured cells suggested that mutant CFTR 
is located in the plasma membrane (31). However that tech- 
nique is probably not sufficiently specific to be certain that 
CFTRAF508 is in the apical membrane.  Finally, a  study 
using Western blots of proteins from CF airway epithelia, 
suggested that mutant protein is processed and glycosylated 
correctly, although no assessment of its location could be ob- 
tained (35). 
Nevertheless, if CFTRAF508 retains some C1- channel 
activity, it is imperative that its location be determined. If 
CFTR is not at the apical membrane, then therapeutic inter- 
ventions designed to increase the function of mutant CFTR 
without affecting its localization are unlikely to appreciably 
alter transepithelial C1- transport. 
There are several  requirements for testing the hypothesis 
that  CFTRAF508  is  not  in  the  apical  membrane of CF 
epithelia. First, it requires nonrecombinant normal and CF 
epithelia. Because the protein processing studies were done 
with recombinant cells, there has been concern that defective 
trafficking could be an artifact of overexpressing CFTR or 
of expressing it in nonpolarized cell lines. For our study, we 
used airway epithelial cells because numerous studies have 
shown that they express the CF defect in C1- permeability 
in their apical membrane and because their dysfunction  con- 
tributes to disease (8, 27). We used primary cultures rather 
than cell lines, because transformation could conceivably al- 
ter protein expression or processing. Finally, we cultured the 
cells on filter supports so that they formed polarized epithelia 
with a distinct apical membrane that expresses the CF defect. 
Second,  a  method is  required that determines if mutant 
CFTR is in the apical membrane, because that is where the 
CF defect in C1- permeability resides. Direct evidence that 
CFTR is in, rather than just near the membrane, is also re- 
quired to avoid ambiguity in the interpretation. Third, well 
characterized antibodies are required. We used mAbs that 
were previously shown to recognize CFTR (14,  18). These 
antibodies also recognize CFTRAF508 (18 and see Materials 
and Methods). The fourth requirement is a detection method 
that is sensitive and which clearly distinguishes signal from 
background. This is essential because CFTR is often present 
at low levels in nonrecombinant cells: mRNA levels are very 
low in airway epithelia (a few copies/cell) (30, 33) and the 
protein has been difficult to detect by immunoprecipitation 
or immunoblotting. Sensitivity and specificity are also re- 
quired so that epithelia from different subjects can be com- 
pared. 
Materials and Methods 
Materials 
Biotinylated sheep anti-mouse IgG, FITC-conjugated streptavidin, and fish 
gelatin were purchased from Amersham Corp.  (Arlington Heights, IL). 
Normal goat serum,  mouse IgG,  DL-DTT,  BSA (fraction V), and neur- 
aminidase ('l~ype VM from Clostridium perfringens)  were obtained from 
Sigma Chemical Co.  (St.  Louis, MO). 
Cell Culture 
We  cultured  NIH  3"1"3 cells  that  were  stably  expressing  CFTR  or 
CFTRAF508  (via recombinant retroviral infection) or were mock trans- 
fected (2), 1"84 cells (25), or human airway epithelial cells (4) as previously 
described. The airway epithelial cells were obtained from nine normal pa- 
tients (six from nasal polyps and three from nasal turbinates) and six CF 
patients (nasal polyps). The genotype of the CF cells was AFS08/NI303K 
for  CFI  and  CF4,  AFS08/G542X  for  CF2,  AF508/other  for  CF3, 
other/other for CFS, and AF508/AFS08 for CF6. Data include all specimens 
processed by the lab during the course of the study. One CF culture (CF6) 
was not studied with the antibody/bead complex technique, because it was 
received before the method was developed; these cells were used for immu- 
nostaining. For localization experiments, 3T3 and I'84 cells were seeded on 
MilliceU-HA filters (12 ram, 0.45 gin, Millipore Corp., Bedford, MA) at 
5  x  10  s cells/cm  2. Airway cells were seeded at the same density on Mil- 
licells or on Living Tissue  Substrate filters (Organogenesis Inc.,  Cam- 
bridge, MA) using seeding techniques recommended by the manufacturer. 
Studies  were done when the airway  epithelia had developed a  maximal 
transepithelial  resistance  (200-800  ft. cm2),  between  5  and  12  d  after 
seeding. 
Monoclonal Antibodies 
mAbs against the R domain (M13-1), the carboxyl terminus (M1-4), and the 
first extracellular domain (M6-4) of CFTR all recognize wild-type CFTR 
as previously described  (14,  18).  Fig.  1 shows that they also recognize 
CFTRAFS08.  All three antibodies stained NIH 31"3 fibroblasts expressing 
either wild-type CFTR (Fig. 1, d-f) or CFTRAF508 (Fig. 1, g-i). In con- 
trast, staining of mock-transfected cells (Fig. 1, a-c), which lack CFTR (2) 
was similar to staining with a nonspecific mouse IgG (not shown). Similar 
results were obtained with HeLa cells expressing recombinant CFTR, using 
a hybrid T7/vaccinia virus expression system (17, 28) (not shown). In addi- 
tion, the antibodies stained CF airway epithelia expressing CFTRAF508 
(see Fig.  6).  Thus,  the antibodies recognize both wild-type CFTR and 
CFTRAF508. 
Immunofluorescence Staining 
All cells were stained as previously described for I'84 cells (14). Briefly, 
mucus was removed from epithelial cells by incubating with 5 mM DTT and 
0.2 U/ml neuraminidase for 30 rain at 370C. Cells were washed with PBS 
and fixed for 30 rain with 4 % paraformaldehyde in PBS. Residual aldehydes 
The Journal of Cell Biology, Volume 118,  1992  552 Figure L  Immunofluorescence staining of stably transfected 3T3 cell lines using antibodies against CFTR. Mock transfected cells (a-c) 
and cells expressing CFTR (d-f) or CFTRAF508 (g-i) were stained with mAbs against the R domain, M13-1  (a, d, and g); the carboxyl 
terminus, M1-4 (b, e, and h); or an extracellular domain, M6-4 (c,f, and i). All cells were permeabilized before incubation with antibody. 
Bar, 50 ~m, 
were inactivated by incubation with 50 mM glycine in PBS for 30 rain. For 
some studies, cells were permeabilized by incubating 10-20 rain with 0.2 % 
Triton X-100 in PISS. Nonspecific staining was blocked by incubating ceils 
for 30-60 rain with incubation buffer (PBS containing  t% BSA and 0.1% 
fish gelatin) supplemented with 5 % normal goat serum.  Single filters were 
cut into pieces and the pieces were incubated with the different antibodies. 
Incubation  with  primary  antibody  in incubation  buffer with goat serum 
(M13-1, 5 ttg/ml; M1-4, 25-50/~g/rnl;  M6-4, 25-40 ~tg/ml) was for 2 h at 
room temperature or overnight at 4~  Between antibody incubations, cells 
were washed three times with ice-cold incubation buffer for 5 rain each. Iw 
cubation with secondary antibody was for 1 h at room temperature and with 
FITC-streptavidin for 30 rain. Biotinylated fluorescent beads (~l-~n diam) 
(Cell Bright Beads, Diversified Biotech,  Newton Centre,  MA) were sus- 
pended in incubation buffer with 5% goat sexum and briefly sorticated just 
before use. Filters were inverted over a drop of bead suspension and cells 
were incubated for I-2 h. Filters were washed by gently immersing in 3-5 
changes of PBS. Cells were covered with mounting medium (Gelmount, 
Biomeda Corp., Foster City, CA) and a glass coverslip was placed on the 
ceils. 
Confocal Microscopy  and Bead  Quantitation 
Confocal images were obtained  using the Bio-Ra_.d  MRC-600 confocal im- 
aging system with an argon ion laser (Bio-Rad  Microsciences  Division, 
Cambridge,  MA), To quantitate  binding of beads,  images of several ran~ 
domly selected fields (630  ￿  420/~m)  were collected and the beads were 
counted.  We routinely counted  I0 fields, although occasionally  up to 20 
fields were counted.  Values are expressed  as beads/field  +  SEM. 
The use of bead antibody  complexes may prove to be of value for the 
study of other membrane  proteins.  Although the qoantitation  is not abso- 
lute, it is similar in principle to that obtained with immunogold electron mi- 
croscopic  techrdques~ 
Results and Discussion 
Use of  Fluorescent  Bead~Antibody  Complexes to 
Localize CFTR 
We developed a new technique designed to localize CFTR 
that  is  in  the  apical  membrane  and  provide  a  readily 
quantifiable method for assessing antibody binding. We used 
mAbs that  we have  previously described:  M13-1, raised 
against the R domain; M1-4, against the carboxyl terminus; 
and M6-4, against an extraceUular domain (14, 18). Primary 
cultures of airway epithelial cells were grown on permeable 
filter supports,  so that they formed polarized epithelia with 
a distinct apical membrane. We incubated the apical surface 
of nonpermeabilized airway epithelia with antibody. Then, 
we incubated with biotinylated anti-mouse IgG followed by 
streptavidin.  Finally, we incubated the cells with a suspen- 
sion of biotinylated fluorescent beads. The beads were easy 
to count because of  their large size (~1/~m), uniform shape, 
and high fluorescence  intensity. To detect  CFTR in the apical 
membrane, we used antibody M6-4, directed against an ex- 
tracellular epitope. Our earlier studies had shown that M6-4 
detects CFTR in the membrane of nonpermeabilized cells 
(14).  To  define nonsp~ific binding,  we  used  antibodies 
against intraceUular domains (M13-1 or M1-4), a nonspecific 
mouse IgG,  or omitted primary antibody altogether.  Our 
Denning et aL Abnormal Localization of CFTR in CF Airway Epithelia  553 Figure 2. Binding of antibody/bead complexes to the apical membrane of nonpermeabilized T84 cells. Confocal images (a) were collected 
at the apical surface of T84 cells incubated without primary antibody (1); with antibodies against intracellular  epitopes,  M13-1 (2) and 
M1-4 (3); or with an antibody against an extracellular epitope, M6-4 (4). Cells were then incubated with biotinylated secondary antibody, 
streptavidin,  and biotinylated fluorescent beads. These images show the fluorescent beads against the negligible background  staining of 
the cell monolayer. The number of  beads in each of 10 random fields/sample was determined and the data (b) are expressed as mean number 
of beads/field  +  SEM.  The number of beads/field was significantly different with M6-4 (asterisk) than with the other conditions  (P < 
0.001, analysis of variance).  Bar, 100 ~m. 
previous work had shown that antibodies M13-1 and M1-4 do 
not have access to their epitopes in nonpermeabilized ceils; 
i.e., they only stain permeabilized cells (14).  We reasoned 
that if CFTR is in the apical membrane, more beads would 
bind to the surface of cells incubated with M6-4 than with 
the other antibodies. Although this procedure does not allow 
an absolute quantitation  of CFTR,  it provided an effective 
means  for defining  nonspecific binding  and  for  detecting 
CFTR in the apical membrane. 
To verify the technique, we tested it with 3"84 cells, which 
express CFTR (18)  in the apical membrane (14).  Fig.  2  a 
shows an example of the results; more beads were bound to 
cells incubated with M6-4 (panel 4) than with M13-1 (panel 
2), M1-4 (panel 3), or no primary antibody (panel 1). When 
we counted the number of beads  in  multiple microscopic 
fields, we found significantly more beads/field with antibody 
M6-4 than in the other conditions (Fig. 2 b). These results 
suggest that antibody M6-4 specifically binds CFTR in the 
apical membrane. They also suggest that antibodies against 
intracellular epitopes are appropriate controls. 
We also evaluated the technique using nonpermeabilized 
NIH 3"1"3 fibroblasts. In cells not expressing CFTR (mock), 
the number of  beads/field was similar with antibodies against 
intracellular and extracellular epitopes (Fig. 3). This result 
indicates similar levels of nonspeeific binding for all the anti- 
bodies. In contrast, with ceils expressing wild-type CFTR, 
the  number  of beads/field  was  significantly  greater  with 
M6-4 than with intracellular domain antibodies. This result 
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Figure 3. Binding of antibody/bead complexes to stably transfected 
NIH 3T3 fibroblasts.  Mock transfected  cells or ceils expressing 
wild-type CFTR or CFTRAF508 were incubated with the indicated 
antibody, with nonspecific mouse IgG (IgG) or without primary an- 
tibody (None). Cells were then incubated with biotinylated second- 
ary antibody, streptavidin, and biotinylated fluorescent beads. The 
number of beads  in each of 10 random fields/sample was deter- 
mined and the data is expressed as mean number of beads/field  5: 
SEM. In the CFTR-expressing ceils, the number of beads/field was 
significantly greater for antibody M6-4 (asterisk) than for the other 
conditions  (P <  0.001, analysis of variance). 
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Figure 4. Binding of antibody/bead complexes to the apical mem- 
brane ofa nonpermeabilized normal (N6) and CF (CF5) airway epi- 
thelium.  Primary cultures  of normal and  CF  airway cells were 
grown as epithelia on permeable filter supports. Nonpermeabilized 
monolayers were incubated with the indicated primary antibody, 
biotinylated secondary antibody, streptavidin, and biotinylated flu- 
orescent beads.  Confocal images were collected,  the number of 
beads in each of 10 random fields/sample was determined, and data 
are expressed as mean number of beads/field -I- SEM. The number 
of beads/field was  significantly different (asterisk) for antibody 
M6-4 in the normal cells (P <  0.001, analysis of variance). 
indicates that CFTR is in the plasma membrane where it is 
accessible to M6-4, a conclusion consistent with immunocy- 
tochemical (Fig.  1) and functional (2) studies of these cells. 
When  we did  the  same  experiment  using  cells  expressing 
CFTRAF508,  we  saw  no  difference  in  the  number  of 
beads/field with the different antibodies. The lack of specific 
binding  with  M6-4  suggests  that  CFTRAF508  is  missing 
from  or  is  present  in  markedly  reduced  amounts  in  the 
plasma membrane of recombinant cells. 
Comparison of CF and Normal Airway Epithelia 
Although  our results  with recombinant CFTR  support the 
hypothesis that CFTRAF508  does not reach the membrane, 
the critical test requires nonrecombinant epithelia where the 
CF defect has been well characterized.  Fig. 4 shows binding 
of antibody/bead complexes to the apical membrane of non- 
permeabilized airway epithelia.  The figure compares a  CF 
and a normal epithelium processed on the same day. There 
are three main points.  First,  the number of beads/field was 
similar  with  intracellular  domain  antibodies  (M13-1  and 
M1-4)  and in the absence of primary antibody.  This result 
again suggests that binding with antibodies against intracel- 
lular epitopes represents  nonspecific,  background  binding. 
Second, background binding was similar for normal and CF 
epithelia.  Third,  and  most  importantly,  antibody  M6-4 
bound specifically to normal, but not to CF epithelia.  This 
result suggests that CFTR is in the apical membrane of nor- 
mal epithelia,  but is missing from the apical membrane of 
CF epithelia. 
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Figure 5. Binding of antibody/ 
bead complexes to the apical 
membrane  of  nonpermeabi- 
lized normal and  CF  airway 
epithelia. Data are from nine 
normal  (N1-9) and  five  CF 
(CFI-5) cultures (each from a 
different  subject)  grown  as 
epithelia on permeable filter 
supports.  Nonpermeabilized 
monolayers  were  incubated 
with antibodies against an in- 
tracellular,  M1-4  (m),  or  an 
extracellular,  M6-4  (-),  do- 
main of CFTR.  a  shows  the 
number  of beads/field  mean 
+  SEM, n  =  at least 10 ran- 
dom fields/experiment.  Simi- 
lar results were obtained with 
antibody  MI3-1  or  no  anti- 
body;  (data  not  shown  be- 
cause each was not used in ev- 
ery culture), b shows the data 
from  a  normalized  to  the 
mean value of beads/field for 
antibody M1-4.  The  number 
of beads/field is significantly 
greater with M6-4 than with 
M1-4 in every normal culture 
(P < 0.01, unpaired t test), but 
in none of the CF cultures. 
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airway epithelia; each came from a different  subject. The ab- 
solute level of binding varied from culture to culture, but 
similar variability between experiments was observed with 
"1"84 and 3T3  cells (not shown).  In every normal culture, 
there was a sigm'ficantly greater number of beads/field with 
antibody M6-4 than with the intracellular antibody M1-4, in- 
dicating that CFTR is in the apical membrane. 
In sharp contrast, there was no significant difference be- 
tween the two antibodies in any of the CF epithelia. The 
genotype of the CF cells was AF508/N1303K for CF1 and 
CF4, AF508/G542X  for CF2, AF508/other for CF3, and 
other/other for CF5. The AF508 mutation accounts for ap- 
proximately 76% of the mutations in the American Cauca- 
sian population (24). The N1303K and G542X mutations are 
two of the more common non-AF508 mutations (see ref. 34 
for a review). As with CFTRAF508, CFTR-N1303K is not 
appropriately glycosylated in a recombinant system (9, 19). 
We expect that CFTR-G542X is a truncated protein or, if the 
levels of mRNA are decreased (20), that there is no G542X 
protein at all. 
The difference between normal and CF epithelia is illus- 
trated more clearly in Fig. 5 b, which shows the data from 
Fig. 5 a normalized to the average number of  beads/field ob- 
served with antibody M1-4.  In normal epithelia, binding 
with antibody M6-4 averaged 4.65 +  1.00 times the binding 
with antibody M1-4. Whereas in CF epithelia, binding with 
antibody M6-4 was 1.02 +  0.03 times the binding with anti- 
body M1-4.  Thus,  we conclude that some mutant CFTR 
proteins,  including CFTRAF508,  CFTR-N1303K,  CFTR- 
G542X, and at least one other mutant CFTR, are not present 
or are present at greatly reduced amounts in the apical mem- 
brane of these CF epithelia. 
We considered alternative explanations for the  lack of 
specific binding in CF epithelia. First, an equal number of 
beads could bind to CF cells incubated with intracellular and 
extracellular domain antibodies, if all three epitopes were 
equally accessible at the surface. Such a scenario could re- 
suit from misfolding of mutant CFTR, so that the R domain 
and carboxyl terminus were located extracellularly. This al- 
ternative is unlikely because the number of beads/field was 
similar to that in the absence of primary antibody or with 
nonspecitic mouse IgG (not shown), i.e., background levels. 
Second, the number of beads bound to CF cells incubated 
with M1-4 and M6-4 could be equal if  the CF, but not normal 
cells, were somehow permeabilized or lysed. In this sce- 
nario,  antibodies  against  intra  and extraceUular  epitopes 
would have equal access to CFTR. This interpretation is un- 
likely because the epithelia were treated identically, because 
there was no greater binding with, than without antibody, 
and because antibodies M1-4 or M13-1 were not able to im- 
munostain CFTR unless we first permeabilized the epithelia 
(see below). 
Localization of CFTR in Airway Epithelia 
If mutant CFTR is not in the apical membrane, where is it? 
To begin to address this question, we used the three antibod- 
ies to stain permeabilized epithelia and localized staining 
with a laser scanning confocal microscope. 
Fig. 6 a shows a series of confocal images of a normal air- 
way epithelium stained with mAb M13-1. We saw the same 
pattern with antibodies directed against the other epitopes of 
CFTR. The first image (Fig. 6 a, row 1) is above the plane 
of the apical membrane; subsequent images are taken as the 
plane of focus moves down into the cell monolayer (3-#m 
increments). The most intense staining was encountered at 
the apical membrane (Fig. 6 a, row 2). Then, as the focal 
plane moved down beneath the apical surface, the staining 
intensity decreased. There was, however,  detectable intra- 
cellular staining in some of the cells (Fig. 6 a, rows 3 and 
4).  At the base of the cells, we saw bright spots of fluores- 
cence  (Fig.  6  a,  row  7).  These  most  likely  represent 
autofluorescent collagen fibers in the supporting matrix, be- 
cause they were also observed in cells stained with nonspe- 
cific mouse IgG (Fig. 6 b, row 7) and in the absence of anti- 
body staining (not shown). This pattern of  staining in normal 
epithelia suggests that most CFTR is in or near the apical 
membrane. The results also suggest that there is some intra- 
cellular CFTR. 
We saw a  different staining pattern in airway epithelia 
from a patient homozygous for the AF508 mutation (Fig. 6 
c).  As the plane of focus moved down into the cells, the 
brightest staining was encountered beneath the apical mem- 
brane, in a punctate pattern throughout the cytoplasm (Fig. 
6 c, rows 3-6). Again, we saw the same pattern with antibod- 
ies directed against the other epitopes of CFTR. In this and 
other studies, there was no significant difference in the size 
or morphology of  normal and CF cells. 
The difference in staining patterns between normal and CF 
cells was a consistent timing. We never saw a predominantly 
intracellular pattern in normal epithelia or a predominantly 
apical pattern in these CF cells. Thus, these results support 
the more quantitative data presented above.  They indicate 
that there is defective traflicking of some mutant forms of 
CFTR in CF epithelia. Because of the low level of immuno- 
staining, we have not been able to localize mutant CFTR to 
a  specific  intracellular  organelle.  However,  in  some  CF 
epithelia the pattern appeared to be perinuclear. 
These data allow us to consider additional alternatives for 
the lack of specific antibody binding in CF epithelia (Fig. 5). 
First, binding with M6-4 might be reduced if mutant CFTR 
was appropriately located, but the total amount of  CFTR was 
markedly reduced. The observation that the overall intensity 
of  immunostaining was approximately similar in normal and 
CF epithelia suggests that this is unlikely in every case. How- 
ever, even if  the absolute levels of  mutant CFTR are reduced 
(as a  result of defective processing or mutations causing 
premature termination of CFTR synthesis), our conclusion 
would be the same: there is much less mutant CFTR in the 
apical membrane. Second, although we know M6-4 recog- 
nizes CFTRAF508 in permeabilized cells (Figs. 1 and 6), it 
is possible that CFTRAF508 is present in the apical mem- 
brane, but the epitope for M6-4 (the first extracelhlar loop) 
is no longer located extracellularly. A normal apical mem- 
brane distribution of mutant CFTR with an unexposed epi- 
tope seems unlikely, because we see very different patterns 
of immunostaining in permeabilized normal and CF epithe- 
lia (Fig. 6). 
Conclusions 
These data indicate that CFTR is located in the apical mem- 
brane of  normal airway epithelia. This location places CFTR 
in a position where it can mediate transepithelial CI- trans- 
port; for a CI- channel to govern CI- secretion it must be 
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images of a normal if,15) and 
a  CF  (CF6)  airway  epithe- 
lium.  Normal  (a,  rows  1-7) 
and CF (c, rows 1-7) epithelia 
were stained with monoclonal 
antibody  M13-1. Also  shown 
is a normal epithelium stained 
with  nonspecific  mouse  IgG 
(b,  rows  1-7).  Images were 
collected with the focal plane 
above the cell monolayer (row 
1)  and  at  3-/~m increments 
moving  toward  the  matrix 
support  (row  7).  Epithelia 
were permeabilized before in- 
cubation  with  antibody.  Bar, 
25/~m. 
located in the apical membrane. Of  course we cannot exclude 
the possibility that CFTR is also located beneath the apical 
membrane, perhaps in intracellular vesicles. In fact, we ob- 
served relatively more intracellular staining in airway epi- 
thelia than in T84 cells grown under similar conditions (14). 
In contrast, we could not detect mutant CFTR in the apical 
membrane of CF airway epithelia.  Thus we conclude that 
mutant  CFTR  is  either  entirely  missing  from  the  apical 
membrane of these CF epithelia or the levels are much re- 
duced.  This conclusion  is valid for CFTRAF508,  CFTR- 
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mined mutation.  These results  support the hypothesis that 
celldar  processing of CFTRAF508  is defective  in native 
epithelia (9,  19). Because some recombinant CF-assoeiated 
mutant proteins  are appropriately  glycosylated (9,  19), we 
predict that we would detect surface CFTR in CF epithelia 
bearing such mutations. 
Defective inttacellular  trafficking of mutated proteins has 
also been  observed in  other  genetic  diseases.  In familial 
hyoercholesterolemia,  class 2 mutations of the low density 
lipoprotein  (LDL) receptor  (representing  50%  of all  mu- 
tants) cause intracellular trafficking defects that result in an 
abnormally  glyeosylated and abnormally  located receptor 
(23).  The absence of surface  receptor  leads to a reduced 
clearance  of circulating  LDL  and eventually  to  disease. 
cq-antitrypsin deficiency  has a similar molecular basis (II). 
Several  studies have shown that the apical membrane of 
CF airway epithelia  lacks a cAMP-stimulated  C1- conduc- 
tance  (27).  Although  it  was  clear  that  this  abnormality 
resulted  from mutations in the CFTR CI- channel,  it was 
unclear how mutations lead to a defective  C1- permeability. 
An understanding of why CF epithelia lack C1- permeability 
became even more pressing after the reports that CFTRAF508 
might retain  some C1- channel activity  (13, 16).  Our data 
indicate that CFTRAFS08 and several other mutants are not 
efficiently delivered to the apical membrane. This result can 
explain the CI- impermeability  in most of CE 
These results  have  several  implications.  First,  as previ- 
ously suggested (9), it is possible that variations in disease 
severity might be explained by the location of  different CFTR 
mutants.  For example,  it is possible that some mutations 
code for proteins that reach the apical membrane and those 
might confer a milder phenotype.  Second, the data suggest 
that therapeutic  attempts to open mutant CFTR C1- chan- 
nels are unlikely  to successfully increase  apical C1- perme- 
ability,  when CFTR is not there.  Interestingly,  if a phar- 
macologic method could be discovered for inducing function 
in mutant CFTR, the assay we have developed might identify 
which patients (or CFTR mutations) were amenable to such 
treatment, 
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